Related Experiment Video
Updated: Feb 13, 2026
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Immunotherapy in Merkel cell carcinoma: role of Avelumab
1Department of Internal Medicine, Division of Hematology and Oncology, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, USA.
Abstract:
Merkel cell carcinoma (MCC), a rare skin cancer, is associated with high mortality, especially in a metastatic setting. Though conventional chemotherapy with platinum and etoposide has had high response rates, many of the patients have had early relapse without any effective therapy thereafter. Recently, immune check point inhibitors have shown very good durable responses, leading to the approval of a programmed death-ligand 1 inhibitor Avelumab for these patients. We briefly review the epidemiology and immune basis of the pathogenesis of MCC, which therefore explains the excellent response to check point inhibitors, and throw light on future directions of immunotherapy for this cancer.
Insights
Merkel cell carcinoma (MCC), a rare skin cancer, has poor outcomes. Immune checkpoint inhibitors, like Avelumab, offer durable responses for advanced MCC, improving patient prognosis.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer.
- Metastatic MCC has a high mortality rate.
- Conventional chemotherapy offers limited long-term benefit due to early relapse.
Purpose of the Study:
- To review the epidemiology and immune basis of MCC pathogenesis.
- To explain the efficacy of immune checkpoint inhibitors in MCC.
- To discuss future directions in MCC immunotherapy.
Main Methods:
- Literature review of MCC epidemiology.
- Analysis of immune mechanisms in MCC pathogenesis.
- Review of clinical data for immune checkpoint inhibitors in MCC.
Main Results:
- Immune checkpoint inhibitors, particularly PD-L1 inhibitors like Avelumab, demonstrate significant durable responses in advanced MCC.
- Understanding the immune basis of MCC explains its sensitivity to immunotherapy.
- Avelumab is approved for advanced MCC treatment.
Conclusions:
- Immunotherapy represents a paradigm shift in advanced MCC treatment.
- Targeting immune checkpoints offers durable responses and improved outcomes.
- Further research into immunotherapy combinations and strategies is warranted.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:18Role of Myosin in Cell Migration
Myosin II is a hexamer comprising two heavy chains with globular heads and coiled-coil tails, two regulatory light chains, and two essential light chains. The ATPase sites on the myosin heads hydrolyze ATP, and the released phosphate generates the force for contraction....
01:02Role of Microtubules in Cell Wall Deposition
01:10The Role of Actin and Myosin in Non-muscle Cells
01:02Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
01:23The Role of Culture